<DOC>
	<DOC>NCT00620659</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of MK0249 in treating refractory excessive daytime sleepiness (EDS) in patients with Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) using nasal continuous positive airway pressure (nCPAP) therapy.</brief_summary>
	<brief_title>Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Patient is male or female and is at least 18 years old and less than 65 years old Patient must have a diagnosis of Obstructive Sleep Apnea/Hypopnea Syndrome Patient has been using nCPAP treatment for at least 2 months prior to Visit 1 Patient is willing to stay at a sleep laboratory for 4 full days and nights for observation and assessments Patient is willing to refrain from napping for the duration of the study Patient is pregnant, breastfeeding, or planning to become pregnant within the next 4 months Patient is or has participated in a study with an investigational compound or device within 30 days of signing the informed consent Patient has had asthmarelated visit to the emergency room or hospitalization within 6 months of Visit 1 Patient has donated or received blood products within 8 weeks of signing consent or is planning on doing either for the duration of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>